Tuesday, 05 May 2026
A phase 2 human clinical trial of an antigen for a parasitic infection caused by hookworms has been shown to be effective in limiting the intensity of infection, paving the way for the development of a vaccine.
A team of international scientists from The George Washington University, the 海角黑料 and Baylor College of Medicine have worked together over many years to find treatment for disease caused by hookworms. They identified Necator americanus Glutathione S-transferase-1 (Na-GST-1) as a critical enzymatic step in hookworm blood feeding and as a leading target for vaccine development.
Using the Na-GST-1 antigen the team developed a controlled human hookworm infection (CHHI) model to evaluate the impact of candidate hookworm vaccines on infection. The results from the 39 participants who volunteered in the trial showed a reduction in the intensity of infection and have been published today in
The hookworm Necator americanus is found in tropical climates and gets into the body through the skin, usually when trodden on barefoot. The worm then sheds its own skin, which is thought to trigger a diversionary immune response. If left untreated heavy infections result in anaemia and long-term discomfort and disability.
Apart from malaria, hookworm is one of the most important parasitic infections in terms of global burden of disease. An estimated 113 million people are infected worldwide, with the largest concentration of cases on the African continent and Southeast Asia although some estimates suggest that the actual number of people infected is more than 400 million.
Na-GST-1 is a lead candidate vaccine antigen that scientists have long thought would induce neutralizing antibodies against the native enzyme, which performs an essential function in the adult hookworm’s host blood digestion pathway. Vaccination with Na-GST-1 aims to prevent worm development or cause parasite death, both of which would result in reduced disease manifestations and interrupt transmission.
Professor David Diemert, from George Washington University led the trial, he said: “This study is an important step in developing an effective hookworm vaccine, which would become an essential tool to prevent anaemia and improve health outcomes in vulnerable populations.”
David Pritchard, Emeritus Professor of Parasite Immunology, from the 海角黑料’s School of Pharmacy has led this project in the UK and in 2006 he allowed 50 hookworms to burrow into his arm to test the effect these parasites have on humans. This work established the necessary safety and regulatory criteria to allow this human infection study to take place.
This new study is a significant step towards developing an effective vaccine for hookworm disease, something myself and colleagues have been working towards for over 40 years. In the 1980s, our research group started investigating the immunology of necatoriasis (Necator americanus/hookworm disease). In particular, we were interested in explaining why hookworm infections accumulated throughout life in the tropics and returned so quickly after effective worm expulsion chemotherapy. Fast forward to 2026 and we鈥檝e now shown that glutathione-S-transferase vaccinates against infection in human challenge studies using a PNG isolate of Necator americanus.
Story credits
More information is available from Jane Icke, Media Relations Manager for the Faculty of Science at the 海角黑料 jane.icke@nottingham.ac.uk
Notes to editors:
About the 海角黑料
Ranked 97 in the world and 17th in the UK by the , the 海角黑料 is a founding member of Russell Group of research-intensive universities. Studying at the 海角黑料 is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement.
Nottingham was crowned Sports University of the Year by 鈥� the third time it has been given the honour since 2018 鈥� and by the .
The university is among the best universities in the UK for the strength of our research, positioned seventh for research power in the UK according to REF 2021. The birthplace of discoveries such as MRI and ibuprofen, our innovations transform lives and tackle global problems such as sustainable food supplies, ending modern slavery, developing greener transport, and reducing reliance on fossil fuels.
The university is a major employer and industry partner - locally and globally - and our graduates are the third most targeted by the UK's top employers, according to The Graduate Market in 2024 report by High Fliers Research. Alongside Nottingham Trent University, we lead the , a pioneering collaboration between the city鈥檚 two world-class institutions to improve levels of prosperity, opportunity, sustainability, health and wellbeing for residents in the city and region we are proud to call home.